Full-Time
Area Business Manager
Pharvaris
51-200 employees
Develops oral bradykinin B2 antagonists
Compensation Overview
$160k - $185k/yr
San Francisco, CA, USA
In Person
Field-based role requiring regular travel throughout the assigned geography, including occasional overnight and weekend travel.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Pharvaris
See people who can refer or advise you
- Minimum of 5+ years of biotechnology or pharmaceutical sales experience, preferably within rare disease, specialty, immunology, or allergy markets.
- Demonstrated success managing complex territories and driving sustained business growth.
- Experience engaging specialty healthcare providers and navigating complex patient access environments.
- Strong understanding of compliant pharmaceutical selling practices and industry regulations.
- Proven ability to work effectively across cross-functional teams in a dynamic commercial environment.
- Excellent communication, organizational, and territory management skills.
- Ability to travel regularly throughout the assigned geography, including occasional overnight and weekend travel.
- A bachelor's degree is required.
- Develop and execute a territory business plan focused on physician engagement, market development, and account growth.
- Drive demand through clinical selling, customer education, and strategic engagement with hereditary angioedema healthcare providers.
- Build and maintain trusted relationships with key customers, thought leaders, and internal business partners.
- Identify opportunities within the territory and adapt strategy based on market dynamics and customer insights.
- Lead field activities including speaker programs, educational initiatives, conference support, peer-to-peer engagement, and customer in-services.
- Partner cross-functionally with Medical, Market Access, Marketing, Patient Services, and Commercial leadership to support patient access and continuity of care.
- Use pre-call planning, territory analytics, and post-call assessment to improve execution.
- Deliver against performance objectives while maintaining compliance and professionalism.
- Contribute to a collaborative, solutions-oriented team culture focused on execution and accountability.
- Product launch experience is strongly preferred.
- A life sciences or business-related bachelor's degree focus is preferred.
- A strategic and proactive approach to territory ownership and business planning.
- Strong clinical and consultative selling capability.
- The ability to influence and build credibility with internal and external stakeholders.
- Experience operating effectively in a fast-paced, evolving commercial organization.
- Strong analytical thinking and the ability to translate insights into action.
- A collaborative mindset paired with competitive drive and executional intensity.
- Emotional intelligence, professionalism, and strong interpersonal presence.
- A patient-focused mentality with a passion for rare disease and improving patient outcomes.
- The confidence to operate independently while remaining connected to the broader team and organizational priorities.
Pharvaris develops oral medications aimed at treating hereditary angioedema (HAE) and other bradykinin B2 receptor–mediated conditions. Its main focus is discovery and development of novel oral bradykinin B2 receptor antagonists that patients can take by mouth rather than by injection. The products work by blocking the bradykinin B2 receptor, which helps reduce or prevent swelling associated with these rare disorders. This approach sets Pharvaris apart from many current therapies that require injections, offering a convenient alternative for patients. The company operates in the clinical-stage biopharmaceutical space, pursuing regulatory approval and eventual commercialization of its oral therapies. Pharvaris’ goal is to provide effective, easier-to-use treatments that improve patient choice and quality of life for people with rare disease conditions.
Company Size
51-200
Company Stage
IPO
Headquarters
Leiden, Netherlands
Founded
2015
Get referred to Pharvaris
See people who can refer or advise you
Simplify's Take
What believers are saying
- May 2026 financing lifted cash to €318 million, funding operations into 2028.
- RAPIDe-3 and CHAPTER-1 presentations at AAAAI and ACAAI strengthened physician awareness in 2026.
- If CHAPTER-3 succeeds, Pharvaris gains a differentiated oral franchise across HAE treatment settings.
What critics are saying
- April 23, 2027 PDUFA can reject deucrictibant, leaving Pharvaris with no approved product.
- CHAPTER-3 Q3 2026 readout can miss efficacy expectations and crush the oral-prophylaxis thesis.
- €318 million cash and recurring losses burn runway if launch delays extend beyond 2028.
What makes Pharvaris unique
- Deucrictibant targets both on-demand and prophylactic HAE with one oral bradykinin antagonist.
- July 2026 FDA NDA acceptance and EMA validation separate Pharvaris from preclinical peers.
- CHAPTER-1 and RAPIDe-3 data support injectable-like efficacy with oral convenience.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Flexible Work Hours
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↑ 0%Pharvaris, a late-stage biopharmaceutical company developing oral treatments for bradykinin-mediated angioedema, reported second quarter 2026 financial results. The company held €318 million in cash and cash equivalents as of 30 June 2026. The FDA is reviewing Pharvaris' New Drug Application for deucrictibant IR, with a PDUFA date of 23 April 2027. The EMA validated the marketing authorisation application in July 2026. Pharvaris expects topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for hereditary angioedema prophylaxis, in the third quarter of 2026. Enrolment continues in CREAATE, a pivotal study for acquired angioedema treatment. The company closed a $132 million underwritten offering in May, extending its cash runway into 2028. Second quarter loss was €47.8 million, with R&D expenses of €35.0 million and G&A expenses of €15.8 million.
Pharvaris NV - FDA sets PDUFA action date for Deucrictibant IR NDA as April 23, 2027. Monday, Jul 6, 2026 6:50 am ET 1min read The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2027, for the New Drug Application (NDA) of deucrictibant immediate-release (IR) for the on-demand treatment of hereditary angioedema (HAE) attacks. This date marks the target by which the FDA aims to complete its review of the application, which is expected to be submitted in the first half of 2026. Pharvaris, a late-stage biopharmaceutical company, has been preparing the NDA dossier based on data from the RAPIDe-3 and RAPIDe-2 trials. The RAPIDe-3 study, a pivotal global Phase 3 trial, demonstrated that deucrictibant IR met its primary endpoint, with median time to onset of symptom relief of 1.28 hours, significantly faster than placebo. The company also plans to present additional data from these trials at upcoming medical congresses. The NDA filing is part of Pharvaris' broader strategy to commercialize deucrictibant for both on-demand and prophylactic treatment of HAE attacks. The company remains on track to submit the NDA in 1H2026, with clear timeline for regulatory review provided by the PDUFA date. Pharvaris also continues to advance its clinical development programs, including the ongoing CREAATE study for AAE-C1INH and the CHAPTER-3 trial for long-term prophylaxis of HAE attacks, with topline data expected in the third quarter of 2026. The company's cash runway extends into the first half of 2027, supporting its current development and commercialization efforts. The FDA's action date reflects the agency's prioritization of the application and provides a key milestone for Pharvaris as it moves toward potential regulatory approval and market launch of deucrictibant IR for HAE.
Pharvaris has priced an underwritten offering of 3,874,664 ordinary shares at $29.68 per share, expecting gross proceeds of approximately $115 million before underwriting discounts and commissions. The biopharmaceutical company has granted underwriters a 30-day option to purchase an additional 581,199 shares. The late-stage company is developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Morgan Stanley, Leerink Partners, Cantor and Wells Fargo Securities are acting as joint book-running managers. The offering is expected to close around 11 May 2026, subject to customary closing conditions. Shares are being offered through an effective shelf registration statement filed with the US Securities and Exchange Commission.
A director at Pharvaris N.V. sold 7,100 shares worth approximately $213,000 through a pre-scheduled Rule 10b5-1 trading plan, according to an SEC filing. The sale represents just 1.8% of director Johannes Schikan's direct holdings, leaving him with 388,067 shares valued at around $10.59 million. The transaction marks Schikan's only sale in the past year and was executed under a pre-arranged plan, indicating planned liquidity management rather than a change in outlook. No indirect holdings or derivative securities were involved in the transaction. Pharvaris, valued at $1.87 billion, is a clinical-stage biopharmaceutical company developing oral therapies for hereditary angioedema. The company's pipeline includes PHA121, PHVS416 and PHVS719, targeting various treatment approaches for the rare disease.
Pharvaris, a late-stage biopharmaceutical company developing oral treatments for bradykinin-mediated diseases, reported cash and cash equivalents of €292 million as of 31 December 2025. The company completed enrollment in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of hereditary angioedema attacks, with topline data expected in third quarter 2026. Pharvaris remains on track to submit a New Drug Application for deucrictibant IR for on-demand treatment of HAE attacks in first half 2026, following positive Phase 3 RAPIDe-3 results. The study demonstrated symptom relief in 1.28 hours and complete resolution in 11.95 hours. Full-year 2025 loss was €176 million, or €2.97 per share, compared to €134 million in 2024. Research and development expenses rose to €124 million from €98.6 million year-over-year.